Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Articles

Recordati’s blockbuster acquisition of EUSA Pharma gives them access to a portfolio of four drugs that treat rare cancers.

Recordati Acquires EUSA Pharma for $845 Million

Fujifilm’s center adds local support in Suzhou, China for cell culture media optimization. 


Fujifilm Irvine Scientific Builds Bioprocessing Innovation and Collaboration Center in China

This collaboration aims to better understand Alzheimer’s and Parkinson’s disease and increase drug discovery and development success rates.

GSK and the University of Oxford Join Forces to Research Treatment Potentials for Neurological Diseases

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

High price tags threaten to block patient access to potentially life-saving cures and treatments.

FDA Grapples with the Promise and Perils of Gene Therapy

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Increased patient-centricity and alternative dosage forms require careful consideration when selecting the best taste-masking approach.

It’s a Matter of Taste-Masking

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Polymeric amorphous solid dispersions are the most commonly used technology, but amorphous APIs remain inherently unstable.

Stabilization of Amorphous APIs

EMA has fully validated the marketing authorization application for Atara Biotherapeutics’ off-the-shelf allogeneic T-cell therapy, tab-cel (tabelecleucel), with an approval decision expected in 2022.

Atara Biotherapeutics' MAA for Allogeneic T-cell Immunotherapy Gets EMA Validation

Particle analysis is a critical component of pharmaceutical development, providing assurances of the quality and performance of the final dosage form.

Not a Particle of Doubt

Chinook Therapeutics has formed a 50/50 joint venture with investors to develop kidney disease therapies in China.

Chinook Therapeutics and Investors Form Joint Venture for Kidney Disease Therapies

Researchers from MIT have developed novel nanosensors for the detection of the nucleocapsid and spike protein of the SARS-CoV-2 virus.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development